-
| Exchange | WAR |
|---|---|
| CurrencyCode | PLN |
| ISIN | PLPHRMN00011 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | 0.75 |
|---|---|
| Target Price | None |
| Market Cap | 37M |
| PE Ratio | None |
| Dividend Yield | None |
Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. It also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, the company is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. operates as a subsidiary of Pelion S.A.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PHR.WAR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026